What the Fleischner Rules Say About an Incidental Lung Nodule

An incidental pulmonary nodule is a small, roughly rounded opacity found on imaging performed for another reason, and it may be a healed infection, intrapulmonary lymph node, scar, inflammatory focus, benign tumor, or early cancer. The image alone often cannot provide immediate certainty.

The Fleischner Society 2017 guideline gives a structured approach for adults with nodules detected incidentally on CT. It deliberately raises the threshold for follow-up of very small nodules because repeated scans create radiation, cost, anxiety, false alarms, and invasive procedures while cancer probability is low.

First ask whether the rules apply#

The guideline does not apply to people younger than 35 because cancer is rare and causes differ. It does not apply in the same way to people with immune compromise, where infection can require prompt evaluation, or to people with a known primary cancer, where a nodule may represent metastasis or a second cancer.

It also does not govern nodules found in a formal screening program. Screening uses scheduled low-dose CT in a population selected for smoking-related risk and commonly applies ACR Lung-RADS. A Lung-RADS category should not be converted casually into a Fleischner row. Symptoms and acute imaging context matter. A nodule amid pneumonia, septic emboli, or another active process may need short-interval reassessment tailored to that condition rather than routine incidental surveillance.

Solid and subsolid are different pathways#

A solid nodule has soft-tissue attenuation that obscures vessels and lung architecture behind it, while a subsolid nodule is either pure ground glass, through which underlying structures remain visible, or part solid, with both ground-glass and solid components.

Transient subsolid nodules often reflect infection or hemorrhage. Persistent subsolid nodules can fall within the adenocarcinoma spectrum and may grow slowly. Their slower natural history is why follow-up lasts longer than for many solid nodules.

The solid component of a part-solid nodule is especially important. Growth of that component can signal invasive behavior even when total diameter changes little. Reports should record both total and solid-component measurements when possible.

How size is measured#

The guideline uses average diameter, calculated from long- and short-axis measurements in the plane where the nodule is largest and rounded to the nearest millimeter, and very small differences can result from slice thickness, inspiration, reconstruction, reader placement, and partial-volume effects.

Thin-section CT, generally 1.5 millimeters or less, improves characterization. A 5-millimeter opacity on a thick reconstruction may not be reliably classified as solid or ground glass; volumetric software can improve growth assessment in some systems, but software versions and segmentation errors need review.

Growth should exceed expected measurement variability. For diameter, a change of about 2 millimeters is commonly treated as meaningful in the Fleischner framework. Volume-doubling time can add information, but irregular shapes and segmentation create uncertainty.

Single solid nodules smaller than 6 millimeters#

For a single solid nodule below 6 millimeters, no routine follow-up is recommended for a lower-risk adult. For a higher-risk adult, an optional CT at 12 months can be considered, especially if morphology is suspicious or the nodule is in an upper lobe.

“No routine follow-up” is not “zero possibility of cancer.” It means expected benefit from scanning everyone is too small relative to harm. A spiculated upper-lobe nodule in a person with heavy smoking history is not managed merely by reading the size row. Conversely, anxiety alone does not make unlimited imaging beneficial, and the conversation should state why the guideline calls this risk low, and what symptom or new piece of information would reopen the question.

Single solid nodules from 6 through 8 millimeters#

For a lower-risk adult, Fleischner recommends CT at 6 to 12 months and then considering another at 18 to 24 months; for a higher-risk adult, CT at both 6 to 12 and 18 to 24 months is recommended.

The interval is a range rather than an exact deadline. Morphology, risk, scan quality, and preferences determine where within the range a follow-up belongs. A scan performed a few days outside the window is not a biologic failure. Stability across the whole solid-nodule surveillance period markedly lowers malignancy probability, although rare exceptions exist, which is why the radiologist should compare directly with the earliest suitable prior examination rather than only the last one.

Single solid nodules larger than 8 millimeters#

For a nodule above 8 millimeters, options include CT at about three months, PET/CT, tissue sampling, or a combination, so the best choice depends on estimated cancer probability, nodule location, procedural risk, comorbidities, and what a result would change.

PET can be false negative in small or low-metabolic tumors and false positive in infection or inflammation. Biopsy can cause pneumothorax or bleeding and can be nondiagnostic. Surgery offers diagnosis and treatment but carries greater burden. Short-interval CT can clarify growth but delays diagnosis if probability is high.

The Chest guideline organizes management around pretest malignancy probability. Low probability may favor surveillance, intermediate probability often benefits from functional imaging or biopsy, and high probability may justify surgical evaluation when you are a candidate; numeric models assist but do not replace judgment.

Multiple solid nodules#

When every solid nodule is smaller than 6 millimeters, lower-risk adults generally need no routine follow-up; higher-risk adults may have optional CT at 12 months. Multiple tiny nodules commonly reflect prior granulomatous disease or intrapulmonary lymph nodes.

If at least one nodule measures 6 millimeters or more, CT at 3 to 6 months is recommended, with later follow-up depending on risk. Management is guided by the most suspicious nodule, which is not always the largest. Spiculation, a growing solid component, or concerning location can outrank size.

Clustering and distribution can suggest infection or inflammatory disease. Multiple nodules should not automatically be called metastatic cancer without a clinical setting that supports it.

Pure ground-glass nodules#

A single pure ground-glass nodule smaller than 6 millimeters generally needs no routine follow-up. Selected nodules near 6 millimeters with suspicious features may be considered for longer follow-up.

For a pure ground-glass nodule at least 6 millimeters, CT at 6 to 12 months confirms persistence, and if unchanged and still pure ground glass, CT every two years until five years is recommended.

The longer horizon reflects slow growth. Stability at two years is not as reassuring for subsolid nodules as for typical solid nodules. At the same time, immediate biopsy of every ground-glass focus would cause substantial overtreatment because many are transient or indolent.

Part-solid nodules#

For a single part-solid nodule smaller than 6 millimeters, the guideline generally gives no routine follow-up because the solid component cannot be measured reliably at that scale. For a nodule at least 6 millimeters, CT at 3 to 6 months confirms persistence.

If the persistent solid component remains smaller than 6 millimeters, annual CT for five years is recommended. A solid component of 6 millimeters or more is highly suspicious and may require diagnostic evaluation rather than routine surveillance. An increase in density or in the solid component can matter even when the overall diameter has not moved, so the two studies need to be read side by side on matching thin reconstructions.

Estimating cancer risk#

Risk rises with age, cumulative smoking, prior smoking-related disease, emphysema, pulmonary fibrosis, family history, larger size, upper-lobe position, spiculation, and certain growth patterns. No factor is deterministic.

Smoking status should be recorded accurately and respectfully. People who never smoked can develop lung cancer, and many nodules in people who smoked are benign. Risk estimates guide a proportional next step rather than assign blame.

Prediction models such as Brock or Mayo can quantify probability in selected settings. Their calibration depends on whether the new patient resembles the development population. A screening-derived model can miscalibrate an incidental-nodule cohort.

Why prior images are so valuable#

An abdominal CT may include the lung bases. A shoulder CT, cardiac CT, or old chest CT can contain the nodule. Direct image comparison is more reliable than relying on a report that used different wording.

Long-term stability of a solid nodule can avoid more radiation and procedures. Growth can shorten the path to evaluation. A report saying “no prior comparison” is an invitation to search other systems and obtain outside studies, not proof that none exist.

Changes in technique complicate comparison. A nodule may look denser or larger on thinner slices. Radiologists account for this by reviewing matching reconstructions and morphology.

Benefits and harms of surveillance#

Surveillance aims to detect clinically important growth while avoiding intervention on benign nodules. Harms include cumulative radiation, incidental findings, anxiety, time, cost, false-positive PET, nondiagnostic biopsy, pneumothorax, bleeding, and surgery for benign disease.

The National Lung Screening Trial demonstrated mortality benefit from low-dose screening in a selected high-risk population, but it also illustrated the volume of positive findings and follow-up. Screening evidence cannot simply justify scanning every incidental nodule, because baseline risk and program design differ. Low-dose technique is generally appropriate for surveillance when diagnostic detail permits, and the order should say it is nodule follow-up so the protocol matches the question being asked.

Communicating the result#

The report should state nodule type, size, location, number, morphology, comparison, and a guideline-based recommendation with its assumptions. “Follow up in one year” is incomplete if it does not say which nodule and why.

The clinician should confirm whether you fit the guideline, estimate risk, search for prior imaging, and assign responsibility for completion. Closed-loop systems reduce missed follow-up. You should leave knowing what the plan is, and knowing that being put under surveillance is not the same as being given a diagnosis.

The ACR appropriateness criteria describe imaging choices for incidental nodules. The British Thoracic Society guideline offers another evidence-based framework using volumetry and risk models. Different guidelines should not be mixed line by line unless you understand their assumptions.

When prompt evaluation is needed#

A small incidental nodule rarely explains acute severe symptoms. If you are coughing blood, newly and significantly breathless, in chest pain, losing weight without explanation, or showing signs of serious infection, those need assessment on their own merits. A highly suspicious report or a nodule above 8 millimeters should not sit in an unmonitored queue.

References#

1. Fleischner Society 2017 guideline
2. ACR Lung-RADS
3. Chest pulmonary nodule guideline
4. British Thoracic Society nodule guideline
5. National Lung Screening Trial overview
6. ACR incidental nodule appropriateness criteria